Skip to content

Use of technologies to monitor and guarantee the treatment of Tuberculosis among Migrants, Refugees and Stateless Persons in Brazil (MIRA-TB Project)

Implementation of technologies for tracking and adherence to treatment of Tuberculosis infection or disease among International Migrants, Refugees and Stateless Persons in Brazil (MIRA-TB Project) - MIRA-TB international migrants, refugees and stateless people with tuberculosis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
REBEC
Registry ID
RBR-49dt8yj
Enrollment
Unknown
Registered
2024-08-13
Start date
2024-08-20
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis. Latent Tuberculosis. Tuberculosis, Pulmonary. Transients and Migrants. Refugees

Interventions

This is a pragmatic study, based on implementation science, whose scope is based on the systematic approach to research problems. The study will be carried out in the five Brazilian cities with the hi

Sponsors

Escola de Enfermagem de Ribeirão Preto da Universidade de São Paulo
Lead Sponsor
Escola de Enfermagem de Ribeirão Preto da Universidade de São Paulo
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Individuals over 18 years old; both gender; international migrants, refugees, and stateless persons diagnosed through the verification of induration (greater than 5 mm) 72 hours after the application of the Tuberculin Test (TT), applied intradermally on the forearm and/or use of the Interferon-Gamma Release Assay (IGRA) in situations where the use of TT is not possible, and according to the protocols of the World Health Organization (WHO); migrants, refugees, and stateless persons with drug-resistant tuberculosis (DR-TB) identified through project screening and/or spontaneous demand at health services, diagnosed according to the protocols of the Ministry of Health (MoH), based on the Rapid Molecular Test (RMT), sputum smear microscopy, or sputum cultur

Exclusion criteria

Exclusion criteria: Lack of familiarity or difficulty using a smartphone; individuals under 18 years old; Brazilians; migrants, refugees, and stateless persons not residing

Design outcomes

Primary

MeasureTime frame
It is expected to find treatment success or adherence efficacy, expressed by the proportion of participants who completed the treatment since randomization. Using adherence tracking and recording methods, the adherence efficacy will be verified by the proportion of participants who complete the treatment.

Secondary

MeasureTime frame
Conduct semi-structured interviews with participants from the three study groups (VDOT, TDO, and TA). Five participants will be randomly selected from each group. The interview approach will use a question guide based on the Behavior Change Wheel (BCW) framework. This theoretical framework addresses key aspects of accepting and adhering to currently prescribed treatments by health services, based on Capability, Opportunity, and Motivation.;Evaluate the incidence of side effects reported and attended to by health services, using medical records and follow-up reports. The percentage of side effects will be measured and compared between study groups. ;Measure satisfaction, costs, stigma, and privacy, using specific questionnaires administered to participants. These parameters will be analyzed and compared between study groups.;Assess the willingness to continue treatment, determined through questionnaires administered to participants at the end of the study period. The percentage of participants who express willingness to continue treatment will be recorded and analyzed.;Evaluate the perception of the importance of treatment for Drug-Resistant Tuberculosis (DR-TB) or Latent Tuberculosis Infection (LTBI), through semi-structured interviews with participants. The percentage of participants who report the importance of the treatment will be quantified.

Countries

Brazil

Contacts

Public ContactRicardo Arcêncio

Escola de Enfermagem de Ribeirão Preto da Universidade de São Paulo

ricardo@eerp.usp.br+55 (16) 33154408

Outcome results

None listed

Source: REBEC (via WHO ICTRP)